Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug

After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. | After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still working out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.